Repaglinide

한글명:Repaglinide

카스 번호135062-02-1

상품명:Repaglinide

CBNumberCB4140539

분자식C27H36N2O4

포뮬러 무게452.59

MOL 파일135062-02-1.mol

화학적 성질

녹는점	129-130.2 °C
알파	D20 +6.97° (c = 0.975 in methanol); D20 +7.45° (c = 1.06 in methanol)
끓는 점	672.9±55.0 °C(Predicted)
밀도	1.137±0.06 g/cm3(Predicted)
저장 조건	2-8°C
용해도	에 용해됨 DMSO: 34mg/mL
물리적 상태	고체
물리적 상태	단단한 모양
산도 계수 (pKa)	4.19±0.10(Predicted)
색상	하얀색
수용성	89.99mg/L(25℃)
Merck	14,8136
InChIKey	FAEKWTJYAYMJKF-QHCPKHFHSA-N
SMILES	C(O)(=O)C1=CC=C(CC(N[C@H](C2=CC=CC=C2N2CCCCC2)CC(C)C)=O)C=C1OCC
CAS 데이터베이스	135062-02-1(CAS DataBase Reference)

위험 및 안전 성명

WGK 독일	2
RTECS 번호	000000033825
HS 번호	2933399090
독성	LD50 orally in rats: >1 g/kg (Grell)

그림문자(GHS)

Repaglinide MSDS

Repaglinide 화학적 특성, 용도, 생산

개요
Repaglinide was marketed in the US as an orally active hypoglycemic agent in patients with a type Ⅱ diabetes mellitus, to lower blood glucose in synergistic combination with metformin, when hyperglycemia cannot be controlled by diet, exercise or metformin alone. Chiral (S)-repaglinide can be synthesized in several ways, each involving a stereoselective reduction of an imine or enamine group. Repaglinide is a nonsulfonylurea belonging to the meglitinide family, with an insulin-releasing effect mediated by pancreatic betacells, by closing the ATP-sensitive K+ channels that, in turn, increases the cytosolic concentration of Ca++. In several animal models, repaglinide was more efficient than glibenclamide as a dose-dependant promoter of insulin release, but its mechanism of action is probably slightly different. Repaglinide has a rapid onset of action, a short duration of action and a reduced risk of hypoglycemia compared to glyburide.
화학적 성질
White to Off-White Solid
용도
The R-enantiomer showed only weak hypoglycemic activity. Repaglinide impurity
일반 설명
Repaglinide is 2-ethoxy-4-[2-[[(1S)-3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]benzoic acid(Prandin); approvals for generics are pending. Combinationsare available with metformin in the United States(Prandimet), and the drug may also be coprescribed with oneof the thiazolidinediones (typically pioglitazone or rosiglitazone;see previous discussion). To establish the most clinicallyvaluable dose, the patient is titrated while monitoringblood glucose levels and hemoglobin glycosylation (HbA1c)as an index of longer-term overall control.
생물학적 활성
K ATP channel blocker that binds with high affinity for SUR1 when co-expressed with Kir6.2 (K d = 0.42 nM). Antidiabetic glucose regulator with hypoglycaemic effect in vivo .
Clinical Use
Repaglinide is a nonsulfonylurea insulin secretagogue that was introduced in the United States in 1998 for type 2 diabetes.

Repaglinide 준비 용품 및 원자재

Repaglinide 공급 업체

Repaglinide 관련 검색

Send Inquriy